![Frontiers | A Personalized Rituximab Retreatment Approach Based on Clinical and B-Cell Biomarkers in ANCA-Associated Vasculitis Frontiers | A Personalized Rituximab Retreatment Approach Based on Clinical and B-Cell Biomarkers in ANCA-Associated Vasculitis](https://www.frontiersin.org/files/Articles/803175/fimmu-12-803175-HTML/image_m/fimmu-12-803175-g001.jpg)
Frontiers | A Personalized Rituximab Retreatment Approach Based on Clinical and B-Cell Biomarkers in ANCA-Associated Vasculitis
![Safety and efficacy of rituximab in systemic sclerosis (DESIRES): a double-blind, investigator-initiated, randomised, placebo-controlled trial - The Lancet Rheumatology Safety and efficacy of rituximab in systemic sclerosis (DESIRES): a double-blind, investigator-initiated, randomised, placebo-controlled trial - The Lancet Rheumatology](https://www.thelancet.com/cms/attachment/9828063d-4162-4a09-b694-7da176effb4a/gr1.gif)
Safety and efficacy of rituximab in systemic sclerosis (DESIRES): a double-blind, investigator-initiated, randomised, placebo-controlled trial - The Lancet Rheumatology
![Schematic illustration of the mechanism of action of rituximab. The... | Download Scientific Diagram Schematic illustration of the mechanism of action of rituximab. The... | Download Scientific Diagram](https://www.researchgate.net/publication/44578445/figure/fig1/AS:314988561485824@1452110533758/Schematic-illustration-of-the-mechanism-of-action-of-rituximab-The-antibody-labels-B.png)
Schematic illustration of the mechanism of action of rituximab. The... | Download Scientific Diagram
![Rituximab, an Anti‐CD20 Monoclonal Antibody: History and Mechanism of Action - Pescovitz - 2006 - American Journal of Transplantation - Wiley Online Library Rituximab, an Anti‐CD20 Monoclonal Antibody: History and Mechanism of Action - Pescovitz - 2006 - American Journal of Transplantation - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/dcd83bb4-f50d-493b-930b-d0cf31662350/ajt_1288_f1.gif)
Rituximab, an Anti‐CD20 Monoclonal Antibody: History and Mechanism of Action - Pescovitz - 2006 - American Journal of Transplantation - Wiley Online Library
![Lymphocyte B antigène CD20 fragment peptidique épitope, lié au rituximab (fragment Fab). Indications pour l'administration de rituximab sont la leucémie et lymphome Photo Stock - Alamy Lymphocyte B antigène CD20 fragment peptidique épitope, lié au rituximab (fragment Fab). Indications pour l'administration de rituximab sont la leucémie et lymphome Photo Stock - Alamy](https://c8.alamy.com/compfr/j5k8a0/lymphocyte-b-antigene-cd20-fragment-peptidique-epitope-lie-au-rituximab-fragment-fab-indications-pour-l-administration-de-rituximab-sont-la-leucemie-et-lymphome-j5k8a0.jpg)
Lymphocyte B antigène CD20 fragment peptidique épitope, lié au rituximab (fragment Fab). Indications pour l'administration de rituximab sont la leucémie et lymphome Photo Stock - Alamy
![The proposed mechanisms of action for rituximab, a chimeric monoclonal... | Download Scientific Diagram The proposed mechanisms of action for rituximab, a chimeric monoclonal... | Download Scientific Diagram](https://www.researchgate.net/publication/230831937/figure/fig1/AS:203082278412288@1425429996137/The-proposed-mechanisms-of-action-for-rituximab-a-chimeric-monoclonal-antibody-against.png)
The proposed mechanisms of action for rituximab, a chimeric monoclonal... | Download Scientific Diagram
![Rituximab, an Anti‐CD20 Monoclonal Antibody: History and Mechanism of Action - Pescovitz - 2006 - American Journal of Transplantation - Wiley Online Library Rituximab, an Anti‐CD20 Monoclonal Antibody: History and Mechanism of Action - Pescovitz - 2006 - American Journal of Transplantation - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/57302335-10b7-4e3f-b402-4d25811a8f1f/ajt_1288_f3.gif)
Rituximab, an Anti‐CD20 Monoclonal Antibody: History and Mechanism of Action - Pescovitz - 2006 - American Journal of Transplantation - Wiley Online Library
![Randomized, Double-Blind, Pharmacokinetic Equivalence Trial Comparing DRL- Rituximab With MabThera in Patients With Diffuse Large B-Cell Lymphoma | JCO Global Oncology Randomized, Double-Blind, Pharmacokinetic Equivalence Trial Comparing DRL- Rituximab With MabThera in Patients With Diffuse Large B-Cell Lymphoma | JCO Global Oncology](https://ascopubs.org/cms/10.1200/JGO.19.00248/asset/images/large/jgo.19.00248f1.jpeg)
Randomized, Double-Blind, Pharmacokinetic Equivalence Trial Comparing DRL- Rituximab With MabThera in Patients With Diffuse Large B-Cell Lymphoma | JCO Global Oncology
![Mechanism of action of rituximab. Rituximab is a monoclonal antibody... | Download Scientific Diagram Mechanism of action of rituximab. Rituximab is a monoclonal antibody... | Download Scientific Diagram](https://www.researchgate.net/publication/221924296/figure/fig3/AS:667588631744528@1536176941819/Mechanism-of-action-of-rituximab-Rituximab-is-a-monoclonal-antibody-directed-against.png)
Mechanism of action of rituximab. Rituximab is a monoclonal antibody... | Download Scientific Diagram
![Clinical review: Serious adverse events associated with the use of rituximab - a critical care perspective | Critical Care | Full Text Clinical review: Serious adverse events associated with the use of rituximab - a critical care perspective | Critical Care | Full Text](https://media.springernature.com/m685/springer-static/image/art%3A10.1186%2Fcc11304/MediaObjects/13054_2012_Article_703_Fig1_HTML.jpg)
Clinical review: Serious adverse events associated with the use of rituximab - a critical care perspective | Critical Care | Full Text
![Frontiers | Past, Present, and Future of Rituximab—The World's First Oncology Monoclonal Antibody Therapy Frontiers | Past, Present, and Future of Rituximab—The World's First Oncology Monoclonal Antibody Therapy](https://www.frontiersin.org/files/Articles/359740/fonc-08-00163-HTML/image_m/fonc-08-00163-g003.jpg)
Frontiers | Past, Present, and Future of Rituximab—The World's First Oncology Monoclonal Antibody Therapy
![Frontiers | Past, Present, and Future of Rituximab—The World's First Oncology Monoclonal Antibody Therapy Frontiers | Past, Present, and Future of Rituximab—The World's First Oncology Monoclonal Antibody Therapy](https://www.frontiersin.org/files/Articles/359740/fonc-08-00163-HTML/image_m/fonc-08-00163-g004.jpg)
Frontiers | Past, Present, and Future of Rituximab—The World's First Oncology Monoclonal Antibody Therapy
![Ofatumumab, a novel anti-CD20 monoclonal antibody for the treatment of B-cell malignancies. | Semantic Scholar Ofatumumab, a novel anti-CD20 monoclonal antibody for the treatment of B-cell malignancies. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/3a4d86a9d30b831243742df33de102bf1fba9eda/2-Figure1-1.png)
Ofatumumab, a novel anti-CD20 monoclonal antibody for the treatment of B-cell malignancies. | Semantic Scholar
![Rituximab Monoclonal Antibody Drug. Targets CD20 on B-lymphocytes Stock Illustration - Illustration of antibody, biotech: 186810711 Rituximab Monoclonal Antibody Drug. Targets CD20 on B-lymphocytes Stock Illustration - Illustration of antibody, biotech: 186810711](https://thumbs.dreamstime.com/z/rituximab-monoclonal-antibody-drug-targets-cd-b-lymphocytes-indications-use-indicate-rheumatoid-arthritis-number-186810711.jpg)